Leishmaniasis (Complete Notes)

Leishmaniasis — MD Pediatrics Note (Based on Nelson Textbook of Pediatrics)

Table of Contents(toc)

Introduction

  • Leishmaniasis is a spectrum of protozoal diseases caused by Leishmania species, transmitted by the bite of infected female phlebotomine sandflies.

    cutaneous leishmaniasis

  • Disease manifestations depend on the species involved and the host immune response.

  • Major clinical forms:

    1. Visceral leishmaniasis (VL / kala-azar)

    2. Cutaneous leishmaniasis (CL)

    3. Mucocutaneous leishmaniasis (MCL)


Etiology and Classification

Form Causative Species Geographic Distribution
Visceral L. donovani, L. infantum (chagasi) South Asia, East Africa, Latin America
Cutaneous L. tropica, L. major, L. mexicana, L. braziliensis Middle East, Africa, Americas
Mucocutaneous L. braziliensis complex Central & South America

Epidemiology

  • Endemic in >80 countries; affects poor, rural populations.

  • Vectors: Phlebotomus (Old World), Lutzomyia (New World).

  • Reservoirs: Humans (L. donovani), dogs, rodents.

  • Transmission: Sandfly bite, rarely congenital or via transfusion.

Phlebotomus

Pathogenesis

  • Inoculation of promastigotes → engulfed by macrophages → transform into amastigotes → intracellular multiplication → spread to RES (liver, spleen, bone marrow).

  • Disease severity depends on cell-mediated immunity (CMI).

    • Strong CMI → localized CL.

    • Poor CMI → disseminated VL.

lifecycle of L donovani

Clinical Features

A. Visceral Leishmaniasis (Kala-azar)

  • Incubation: 2 weeks–18 months.

    Visceral Leishmaniasis (Kala-azar)
  • Onset: Insidious.

  • Major triad:

    1. Fever: Remittent, double-quotidian, or irregular.

    2. Hepatosplenomegaly: Marked splenomegaly, moderate hepatomegaly.

    3. Pancytopenia: due to hypersplenism and marrow infiltration.

  • Other features:

    • Weight loss, wasting, darkening of skin (“kala-azar” = black fever)

    • Lymphadenopathy (esp. African form)

    • Anemia, bleeding, infections (esp. bacterial superinfection)

    • Growth retardation and cachexia in chronic disease.

Post-kala-azar dermal leishmaniasis (PKDL):
  • Occurs months–years after VL cure.

  • Hypopigmented macules, papules, nodules (face, arms, trunk).

  • Serves as a reservoir in endemic areas (notably India).


B. Cutaneous Leishmaniasis

  • Lesion: Painless papule → ulcer with indurated margin (“oriental sore”).

  • Usually heals spontaneously in 3–6 months but leaves scar.

  • Chronic forms may resemble lupus vulgaris.


C. Mucocutaneous Leishmaniasis

  • Extension from cutaneous lesion (nasal/oral mucosa).

  • Causes destructive ulcerations → severe disfigurement.

mucocutaneous leishmaniasis

Laboratory Diagnosis

1. Direct demonstration

  • Amastigotes (Leishman–Donovan bodies) in:

    • Splenic aspirate (most sensitive, but risky)

    • Bone marrow aspirate (safe, moderately sensitive)

    • Lymph node or buffy coat smear

  • Giemsa-stained smears show:

    • Oval amastigotes (2–5 μm) with nucleus and kinetoplast inside macrophages.

2. Culture

  • Novy–MacNeal–Nicolle (NNN) medium → promastigote growth.

3. Serologic tests

  • rK39 dipstick test: Highly sensitive & specific for VL (field use).

  • Direct agglutination test (DAT), IFA, ELISA also available.

4. Molecular tests

  • PCR: Highly sensitive, species-specific; used in reference labs.

5. Hematology

  • Pancytopenia, hypergammaglobulinemia, elevated ESR.


Treatment

First-line (Visceral Leishmaniasis)

  • Liposomal Amphotericin B (preferred):

    • Total dose 10–21 mg/kg (varies by region/protocol)

    • Short-course regimens effective.

  • Alternative:

    • Amphotericin B deoxycholate: 1 mg/kg/day × 15–20 doses (toxic, nephrotoxic)

    • Miltefosine: 2.5 mg/kg/day (max 150 mg/day) × 28 days (oral)

    • Paromomycin (IM): 11 mg/kg/day × 21 days

    • Combination regimens (to prevent resistance):

      • Single-dose liposomal amphotericin B + short-course miltefosine or paromomycin.

Cutaneous Leishmaniasis

  • Local therapy (cryotherapy, intralesional antimony) for small lesions.

  • Systemic therapy for multiple, mucosal, or immunocompromised cases:

    • Miltefosine, liposomal amphotericin B, or pentavalent antimonials.

Mucocutaneous Leishmaniasis

  • Liposomal amphotericin B or pentavalent antimonials for ≥28 days.


Prevention and Control

  • Vector control: Insecticide spraying, bed nets.

  • Reservoir control: Treat dogs, cull infected reservoirs.

  • Personal protection: Repellents, protective clothing.

  • Early diagnosis and treatment reduce transmission.

  • Vaccine: None yet in routine use; trials ongoing.


Complications

  • Secondary bacterial infections

  • Severe anemia, hemorrhage

  • Disseminated infection in HIV patients

  • PKDL (in endemic regions like India/Nepal)


Prognosis

  • Excellent with prompt diagnosis and treatment.

  • Mortality >90% if untreated (mainly from secondary infections, cachexia).


Key Points from Nelson

  • Visceral leishmaniasis should be suspected in any febrile child with splenomegaly and pancytopenia in an endemic area.

  • rK39 test is the diagnostic test of choice in field settings.

  • Liposomal amphotericin B is the preferred therapy in both immunocompetent and immunocompromised children.

  • PKDL represents an important reservoir for ongoing transmission.

  • HIV co-infection complicates disease course and increases relapse risk.

Fanconi Anemia Notes for Doctors and PG Aspirants

Fanconi Anemia (FA)

Table of Contents(toc)

Category: Inherited bone marrow failure syndrome (IBMFS)
Inheritance: Autosomal recessive (rarely X-linked)
Gene defects: >22 genes identified (FANCA, FANCC, FANCG most common) → defective DNA interstrand crosslink repair.

fanconi anemia notes

1. Pathophysiology

  • Defect in DNA repair (Fanconi/BRCA pathway) → chromosomal breakage and hypersensitivity to DNA cross-linking agents (e.g., mitomycin C, diepoxybutane).

  • Progressive bone marrow failure (due to stem cell depletion) and genomic instability → predisposition to malignancies.

  • Multisystem developmental abnormalities due to impaired cell proliferation during embryogenesis.


2. Epidemiology

  • Incidence: ~1 in 100,000–250,000 live births.

  • Carrier frequency: ~1 in 200.

  • Median age of diagnosis: 7–9 years.

  • ~90% develop marrow failure by age 40.


3. Clinical Features

A. Hematologic

  • Pancytopenia (usually first manifests with thrombocytopenia or macrocytic anemia).

  • Progressive bone marrow hypoplasia.

  • Increased fetal hemoglobin (HbF).

  • Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) risk ↑ markedly.

B. Physical anomalies (present in ~75%)

  • Growth: Short stature, low birth weight.

  • Skeletal: Radial ray defects—absent/hypoplastic thumb, radius anomalies.

  • Skin: Café-au-lait spots, hypopigmentation, hyperpigmentation.

  • Head/Face: Microcephaly, triangular face, microphthalmia.

  • Genitourinary: Renal agenesis, horseshoe kidney, hypoplastic gonads, undescended testes, infertility.

  • Cardiac: Structural heart defects.

  • ENT: Hearing loss.

  • GI: Duodenal atresia, anal anomalies (occasionally).

C. Endocrine/Metabolic

  • Hypothyroidism, glucose intolerance, gonadal failure, low IGF-1.

D. Malignancy risk

  • AML, MDS, and solid tumors (esp. head & neck SCC, gynecologic SCC, liver tumors) due to chromosomal instability.


4. Investigations

Test Finding/Use
CBC Pancytopenia, macrocytosis, increased HbF
Bone marrow biopsy Hypocellular marrow with fatty replacement
Chromosomal breakage test Diagnostic — increased breaks after exposure to diepoxybutane (DEB) or mitomycin C
Molecular genetic testing Confirms FANCA–FANC gene mutations
Flow cytometry for CD34 Decreased hematopoietic stem cells
Ultrasound abdomen Renal anomalies
Endocrine profile Hypothyroidism, gonadal failure screening

5. Differential Diagnosis

  • Acquired aplastic anemia

  • Dyskeratosis congenita

  • Shwachman-Diamond syndrome

  • Diamond–Blackfan anemia


6. Management

Supportive

  • Regular CBC monitoring.

  • Transfusion support (RBCs, platelets) — minimize iron overload.

  • Iron chelation therapy if ferritin ↑.

  • Androgens (e.g., oxymetholone, danazol) → stimulate erythropoiesis (transient benefit).

  • G-CSF for neutropenia (short-term).

  • Avoid DNA-damaging agents (chemotherapy, radiation).

Curative

  • Allogeneic hematopoietic stem cell transplantation (HSCT)only curative therapy for marrow failure.

    • Ideal: HLA-matched sibling donor.

    • Conditioning regimens: low-intensity to minimize toxicity (avoid alkylators, irradiation).

Malignancy surveillance

  • Annual oral, gynecologic, and dermatologic exams.

  • CBC every 3–6 months.

  • Avoid smoking, alcohol, and UV exposure.

Endocrine and developmental care

  • Hormonal replacement as indicated (thyroid, sex steroids, GH).

  • Orthopedic/surgical correction for congenital anomalies.


7. Prognosis

  • Median survival (without HSCT): ~20–30 years.

  • With HSCT: markedly improved, though risk of secondary malignancy persists.

  • Lifelong surveillance for cancer and organ dysfunction required.


8. Key Points for Exams

  • Classic triad: Bone marrow failure + congenital anomalies + cancer predisposition.

  • Diagnostic hallmark: Chromosomal breakage test positive with DEB/Mitomycin C.

  • Curative therapy: HSCT.

  • Common mutation: FANCA.

  • AML/MDS risk: markedly increased.

  • Androgens improve counts transiently but cause virilization/hepatotoxicity.

नाडीबाट रगत किन निकालिन्छ (मुख्य कारण)?

 नाडीबाट रगत किन निकालिन्छ ?

Table of Contents(toc)

हामी प्रायः रगत परीक्षणका लागि हातको नसाबाट (vein) रगत निकालिन्छ भन्ने कुरा जान्दछौं। तर कहिलेकाहीँ स्वास्थ्यकर्मीले नाडीबाट (artery) पनि रगत निकाल्छन्। यो सामान्य रगत परीक्षणभन्दा फरक र विशिष्ट उद्देश्यका लागि गरिन्छ।

ABG sampling technique why and when

 नाडीबाट रगत निकाल्नुको मुख्य कारण — “Arterial Blood Gas (ABG)” परीक्षण

नाडीबाट रगत निकाल्ने मुख्य उद्देश्य Arterial Blood Gas (ABG) test हो।
यो परीक्षणले शरीरमा रहेका अक्सिजन (O₂), कार्बन डाइअक्साइड (CO₂)रगतको अम्ल–क्षार (pH) सन्तुलन कस्तो छ भन्ने देखाउँछ।

यो जानकारी फोक्सो र मुटुको कार्य कस्तो छ भन्ने बुझ्न अत्यन्त जरुरी हुन्छ।


यो परीक्षण कहिले गरिन्छ ?

  1. जब बिरामीलाई अक्सिजन कमी (hypoxia) को शंका हुन्छ।

  2. सास फेर्न गाह्रो भएको अवस्थामा (जस्तै– दमा, COPD, pneumonia, ARDS)।

  3. भेन्टिलेटरमा राखिएका बिरामीहरूमा, अक्सिजनको मात्रा ठिक छ कि छैन भनेर हेर्न।

  4. गम्भीर रोगीहरूमा, अम्ल–क्षार सन्तुलन (acid–base balance) पत्ता लगाउन।

  5. सर्जरीपछि वा गम्भीर संक्रमण (sepsis) भएका बिरामीहरूमा।


कुन नाडीबाट निकालिन्छ ?

सबैभन्दा धेरै प्रयोग हुने नाडीहरू:

  • Radial artery (कलाईको नाडी) – सबैभन्दा सामान्य र सुरक्षित।

  • Femoral artery (जाँघको नाडी) – आपतकालमा प्रयोग।

  • Brachial artery (काँधतर्फको नाडी) – कहिलेकाहीँ प्रयोग।

ABG गर्नुअघि प्रायः Allen’s test गरिन्छ, जसले हातको रक्तप्रवाह सुरक्षित छ कि छैन भन्ने पक्का गर्छ।


कसरी निकालिन्छ ?

  1. बिरामीलाई आराम दिन्छ।

  2. छालालाई सफा गरिन्छ (antiseptic)।

  3. नाडीको धड्कन भेटाएर सुई प्रयोग गरी सिधै नाडीभित्र सुई प्रवेश गरिन्छ।

  4. रगत सिधै syringe मा स्वचालित रूपमा भरिन्छ, किनकि नाडीको दबाब (pressure) बढी हुन्छ।

  5. त्यसपछि तुरुन्तै syringe लाई बर्फमा राखी ल्याबमा पठाइन्छ ताकि ग्यासहरू नबदलिऊन्।


नसाबाट होइन, नाडीबाट किन ?

नसाको रगतले शरीरको अक्सिजन र कार्बन डाइअक्साइडको सन्तुलन सही रूपमा देखाउँदैन, किनभने त्यो पहिले नै ऊतकहरूबाट फर्किएको हुन्छ।
तर नाडीको रगत भने फोक्सोबाट निस्किएको ताजा अक्सिजनयुक्त रगत हो, जसले शरीरको साँच्चिकै ग्यास स्थिति जनाउँछ।

त्यसैले फोक्सो, सासफेर्ने प्रणाली वा अक्सिजन थेरापी मूल्याङ्कन गर्न नाडीबाट रगत आवश्यक पर्छ।


के जोखिम हुन्छ ?

सामान्यतया सुरक्षित भए पनि केही साइड इफेक्ट हुन सक्छन् —

  • नाडीमा दबाबको कारण दुखाइ वा निलो दाग (bruise)

  • कहिलेकाहीँ रगत बग्ने वा clot बन्ने समस्या

  • धेरै पटक सुई लगाउँदा नाडीको क्षति वा हात सुन्निनु

त्यसैले यो परीक्षण प्रशिक्षित स्वास्थ्यकर्मी (जस्तै चिकित्सक वा नर्स) ले मात्र गर्नुपर्छ।


सारांशमा

नाडीबाट रगत निकाल्नु साधारण परीक्षण होइन, तर अत्यन्त महत्त्वपूर्ण चिकित्सकीय प्रक्रिया हो जसले शरीरको अक्सिजन, कार्बन डाइअक्साइड र अम्ल–क्षार सन्तुलनबारे सटीक जानकारी दिन्छ।
यसले चिकित्सकलाई बिरामीको सासफेर्ने स्थिति बुझ्न, भेन्टिलेटर मिलाउन, र उपचारको प्रभाव मूल्याङ्कन गर्न मद्दत गर्छ।

Episodic vs Multitrigger Wheeze (differences)

Introduction



Wheezing is a common symptom in preschool children due to small airway size and frequent viral infections.
To better characterize wheezing phenotypes in early childhood, the European Respiratory Society (ERS) task force proposed two main categories:

  1. Episodic (viral) wheeze (EVW)
  2. Multi-trigger wheeze (MTW)

These terms help predict prognosis and guide management.


1. Episodic (Viral) Wheeze (EVW)

Definition

Wheeze that occurs only during discrete viral respiratory infections, with no symptoms in between episodes.

Age Group

  • Common in 1-5 years (preschool).
  • Often resolves by school age.

Typical Clinical Features

FeatureDescription
TriggerExclusively viral URTI (rhinovirus, RSV, etc.)
Interval SymptomsNone – child is asymptomatic between episodes
AtopyUsually absent
Family historyOften negative for asthma/allergy
Night-time cough/wheeze without coldAbsent
Response to bronchodilatorVariable, sometimes good
Response to inhaled corticosteroids (ICS)Poor to moderate (benefit only during acute episodes)

Pathophysiology

  • Due to viral-induced airway inflammation and narrowing.
  • No persistent airway inflammation like in asthma.

Prognosis

  • Usually outgrows by 6 years as airway caliber increases.
  • Only a small fraction progress to asthma.

2. Multi-Trigger Wheeze (MTW)

Definition

Wheeze that occurs not only with viral infections but also with other triggers such as allergens, exercise, laughter, crying, or exposure to smoke.

Age Group

  • May start in preschool years but often persists into school age.

Typical Clinical Features

FeatureDescription
TriggerViral + non-viral (exercise, allergens, smoke, crying, etc.)
Interval SymptomsPresent even between viral infections
AtopyCommon
Family historyOften positive for asthma/allergy
Night-time cough/wheezeCommon
Response to bronchodilatorGood
Response to ICSGood (similar to asthma)

Pathophysiology

  • Reflects persistent airway inflammation and hyper-responsiveness, similar to asthma.
  • Considered an early asthma phenotype.

Prognosis

  • High risk of developing persistent asthma later in life.

Comparison Table

FeatureEpisodic (Viral) WheezeMulti-Trigger Wheeze
Between episodesNo symptomsSymptoms persist
TriggersViral infections onlyViral + other (exercise, allergens, smoke, etc.)
Family/atopy historyUsually absentOften present
Night symptomsAbsentPresent
Response to ICSPoor/limitedGood
PrognosisResolves by school ageOften persists (asthma risk)

Investigations (for exam answers)

Usually clinical diagnosis based on history.

But if evaluation is needed:

  • Spirometry: Often normal between attacks in EVW; reversible obstruction in MTW.
  • Allergy testing: Negative in EVW, positive in MTW.
  • Fractional exhaled nitric oxide (FeNO): Higher in MTW (marker of eosinophilic inflammation).

Management

StepEpisodic WheezeMulti-Trigger Wheeze
Acute episodeSABA (salbutamol) and/or oral steroid (short course)SABA and/or oral steroid
Controller therapyICS intermittent during viral illness; daily ICS not recommendedDaily low-dose ICS (preventer) + as-needed SABA
Other optionsMontelukast may reduce episode frequencyMontelukast may help but less effective than ICS
Follow-upReassess after 6-12 monthsStep up/down therapy as per asthma guidelines

Key Take-Home for Exam

  • Episodic (viral) wheeze = no symptoms between episodes.
  • Multi-trigger wheeze = symptoms triggered by multiple factors and persistent between colds.
  • Multi-trigger = closer to asthma phenotype.
  • ICS helpful only in multi-trigger type.
  • Most episodic wheezers outgrow symptoms by 6 years.

MCQs for Practice

1. A 3-year-old boy has recurrent wheezing episodes associated only with colds. Between episodes, he is symptom-free. The most likely diagnosis is:
A. Bronchial asthma
B. Episodic (viral) wheeze
C. Multi-trigger wheeze
D. Reactive airway disease
Answer: B – Episodic (viral) wheeze


2. Which of the following features favors multi-trigger wheeze?
A. No symptoms between viral infections
B. Absence of family history of atopy
C. Night-time cough in absence of cold
D. Poor response to inhaled corticosteroids
Answer: C – Night-time cough in absence of cold


3. The typical age for onset of episodic viral wheeze is:
A. Neonatal period
B. 6 months – 5 years
C. After 10 years
D. Adulthood
Answer: B – 6 months to 5 years


4. Most preschool children with episodic viral wheeze:
A. Progress to asthma
B. Develop COPD later
C. Outgrow symptoms by 6 years
D. Have severe atopy
Answer: C – Outgrow symptoms by 6 years


5. Which of the following statements is TRUE regarding multi-trigger wheeze?
A. Symptoms occur only during viral infections
B. Often associated with atopy and family history of asthma
C. No response to bronchodilator
D. Resolves completely by 2 years
Answer: B – Associated with atopy and family history


Viva Questions & Model Answers

Q1. What is the most common cause of wheeze in preschool children?
Viral infection-induced wheeze (episodic wheeze).

Q2. How do you differentiate episodic wheeze from asthma in a 4-year-old?
Episodic wheeze: symptoms only during viral infection, asymptomatic between episodes; Asthma (multi-trigger): symptoms even without infection, with triggers like exercise and night cough.

Q3. What is the management difference between episodic and multi-trigger wheeze?
Episodic: intermittent therapy during viral illness; Multi-trigger: daily controller (ICS).

Q4. What is the role of Montelukast in preschool wheezers?
Can reduce frequency/severity of viral-induced episodes, but benefit modest.

Q5. What is the long-term outcome of each phenotype?
Episodic: often resolves by 6 years; Multi-trigger: may progress to asthma.


Summary Points for Rapid Revision

  • Episodic wheeze = viral-only, Multi-trigger = viral + others
  • No interval symptoms – Episodic
  • Interval symptoms – Multi-trigger
  • Atopy & night symptoms – Multi-trigger
  • ICS helps only in multi-trigger
  • Prognosis better in episodic type

Splenomegaly Full Note for Internal Medicine and Pediatrics

Splenomegaly – Clinicals and Differentials

Table of Contents(toc)
splenomeglay illustration

Definition

Splenomegaly is enlargement of the spleen beyond its normal size (normally not palpable below the left costal margin).

  • Normal weight: ~150–200 g

  • Normal length: ~11 cm

  • Massive splenomegaly: Spleen palpable below the umbilicus or crossing the midline.


Anatomy & Physiology Summary

  • Functions: Filtration of old RBCs, immune surveillance, hematopoiesis (fetal), platelet and RBC reservoir.

  • Normal spleen not palpable; becomes palpable when enlarged ≥2–3×.


Classification of Splenomegaly

Type Spleen size Examples
Mild (2–3 cm) Slight enlargement Viral infections, hemolysis
Moderate (3–8 cm) Reaches midway to umbilicus Malaria, portal hypertension
Massive (>8 cm / crosses midline) Large spleen CML, myelofibrosis, Kala-azar

Pathophysiology / Mechanisms

  1. Increased workload (reticuloendothelial hyperplasia)
    → Infections, hemolysis

  2. Congestive (venous pooling)
    → Portal hypertension, splenic vein thrombosis

  3. Infiltrative / Neoplastic
    → Leukemia, lymphoma, storage diseases

  4. Immune / Inflammatory
    → SLE, rheumatoid arthritis (Felty’s syndrome)

  5. Extramedullary hematopoiesis
    → Myelofibrosis, severe thalassemia


Causes / Differential Diagnosis of Splenomegaly

1. Infective Causes

  • Acute infections:

    • Infective mononucleosis (EBV)

    • Viral hepatitis

    • Typhoid fever

    • Infective endocarditis

    • Sepsis (esp. in children)

  • Chronic infections:

    • Malaria

    • Kala-azar (Visceral leishmaniasis)

    • Tuberculosis

    • Schistosomiasis

    • Brucellosis


2. Hematological Causes

  • Hemolytic anemias

    • Thalassemia major/intermedia

    • Hereditary spherocytosis

    • Sickle cell disease (early phase)

    • Autoimmune hemolytic anemia

  • Leukemias & Lymphomas

    • Chronic myeloid leukemia (CML) → massive splenomegaly

    • Chronic lymphocytic leukemia (CLL)

    • Hairy cell leukemia

    • Hodgkin / Non-Hodgkin lymphoma

  • Myeloproliferative / Myelofibrotic disorders


3. Congestive / Portal Causes

  • Portal hypertension (cirrhosis, extrahepatic portal vein obstruction)

  • Splenic vein thrombosis

  • Right heart failure, constrictive pericarditis


4. Storage / Infiltrative Disorders

  • Gaucher’s disease

  • Niemann–Pick disease

  • Amyloidosis

  • Sarcoidosis


5. Autoimmune / Inflammatory

  • Systemic lupus erythematosus (SLE)

  • Rheumatoid arthritis (Felty’s syndrome)

  • Autoimmune hepatitis


6. Miscellaneous / Rare

  • Cysts, abscess, hydatid disease

  • Primary splenic tumor (hemangioma, angiosarcoma)

  • Secondary metastasis (rare)


Massive Splenomegaly (Mnemonic: CHAMPS)

  • C – Chronic myeloid leukemia

  • H – Hairy cell leukemia

  • A – Agnogenic myeloid metaplasia (myelofibrosis)

  • M – Malaria (chronic)

  • P – Portal hypertension / Kala-azar

  • S – Storage diseases (Gaucher, Niemann-Pick)

massive splenomegaly in CT scan

Clinical Features

  • Fullness or dragging sensation in LUQ

  • Early satiety

  • Pain due to infarction or capsule stretch

  • Hypersplenism → Anemia, leukopenia, thrombocytopenia

  • Palpable firm or hard spleen below costal margin


Investigations

  • CBC & Peripheral smear: cytopenias, abnormal cells

  • LFT, RFT

  • Viral markers (EBV, hepatitis, HIV)

  • Bone marrow examination

  • Ultrasound / CT abdomen: spleen size, portal system, lymphadenopathy

  • Serology: malaria, kala-azar (rk39), brucella

  • Liver biopsy / portal venography if portal cause suspected


Complications

  • Hypersplenism → cytopenias

  • Splenic rupture (trauma or spontaneously in infections)

  • Splenic infarction

  • Portal hypertension


Management

  • Treat underlying cause (infection, hematologic disorder, etc.)

  • Avoid trauma / contact sports

  • Splenectomy – indicated in:

    • Hypersplenism with cytopenias unresponsive to therapy

    • Hereditary spherocytosis

    • Immune thrombocytopenic purpura (refractory)

    • Splenic abscess, cyst, rupture

  • Vaccinations before splenectomy: Pneumococcal, Hib, Meningococcal


Key Examination Tips

  • Always examine in right lateral position

  • Start palpation from right iliac fossa towards LUQ

  • Note size, consistency, tenderness, notching, relation to costal margin


Summary Table

Mechanism Common Causes
Infective Malaria, Kala-azar, EBV
Hemolytic Thalassemia, HS, AIHA
Neoplastic CML, Lymphoma
Congestive Cirrhosis, Portal HTN
Storage Gaucher, Niemann-Pick
Autoimmune SLE, Felty’s
Miscellaneous Cyst, Abscess

Steroid Dosing in Nephrotic Syndrome (Prednisolone and Prednisone dose in Nephrotic Syndrome) and clinical scenarois

MD-Level Note: Steroid Dosing in Nephrotic Syndrome

Table of Contents(toc)
Here is MD level Note on Dose of Steroids in Nephrotic Syndrome.
checking oedema in nephrotic syndrome


1. Standard (First Episode) Nephrotic Syndrome

Guideline Reference:

Dose:

Prednisolone 2 mg/kg/day (maximum 60 mg/day) for 6 weeks, followed by
1.5 mg/kg on alternate days (maximum 40 mg) for next 6 weeks.

Rationale:

Practical Example 1:

A 20 kg child presents with first episode NS.

  • Daily dose: 2 mg/kg = 40 mg daily × 6 weeks.

  • Then alternate-day: 1.5 mg/kg = 30 mg on alternate days × 6 weeks.

  • Total course: 12 weeks.

Avoid: tapering below alternate day dose before completion of 12 weeks — increases relapse.


2. Relapsing Nephrotic Syndrome

a. Infrequent Relapser

  • <2 relapses in 6 months or <3 in 1 year.

Dose:

Prednisolone 2 mg/kg/day until remission (urine protein nil/trace × 3 days),
then 1.5 mg/kg on alternate days for 4 weeks, then stop.

Example:
Child relapses after 5 months remission → give daily 2 mg/kg till protein nil ×3 days → shift to 1.5 mg/kg AD ×4 weeks → stop.


b. Frequent Relapser

  • ≥2 relapses in 6 months or ≥4 in 12 months.

Dose:
Same as above for each relapse, but consider tapering or steroid-sparing agent.

Maintenance (if steroid-only used):

Alternate day 0.5–0.7 mg/kg prednisolone for 3–6 months.

Example:
If child relapses every 2 months — after inducing remission, maintain on 0.5 mg/kg AD for 6 months to break cycle.


c. Steroid-Dependent Nephrotic Syndrome (SDNS)

  • Relapse during tapering or within 2 weeks of stopping steroids.

Strategy 1: Low-dose alternate-day steroids

Maintain remission with 0.3–0.5 mg/kg AD for 6–12 months.

Strategy 2: Add steroid-sparing agent

Cyclophosphamide, levamisole, MMF, or calcineurin inhibitor depending on toxicity and previous exposure.

Example:
A 7-year-old develops relapse each time dose falls below 0.5 mg/kg AD → maintain at 0.5 mg/kg AD × 6 months; if Cushingoid, add levamisole.


d. Steroid-Resistant Nephrotic Syndrome (SRNS)

  • No remission after 6 weeks of daily 2 mg/kg prednisolone.

Confirm compliance, dose accuracy, and rule out secondary NS before labeling SRNS.

Protocol:

Continue same dose for total 6–8 weeks before biopsy and calcineurin inhibitor introduction.

Example:
A 6-year-old on pred 2 mg/kg × 6 weeks still 3+ protein — if compliance ensured, classify as SRNS, proceed to biopsy.


3. Partial Responders or Slow Responders

If urine protein reduces but not nil after 6 weeks →
continue full dose 2 mg/kg/day for additional 2 weeks before deciding resistance.


4. Relapse While on Alternate-Day Therapy

Switch to 2 mg/kg/day until remission × 3 days,
then back to alternate-day baseline dose for 4 weeks.


5. Relapse While on Daily Steroid (e.g., during infection)

Do not increase dose; continue same daily dose until infection settles.
After remission, taper normally.


6. Special Scenarios

a. Grossly Edematous Child

  • Use IV methylprednisolone (10–15 mg/kg/day × 3 days) if poor oral absorption suspected, then switch to oral 2 mg/kg/day.

  • Confirm no hypovolemia before diuretics.

b. Infantile Nephrotic Syndrome (<1 yr)

  • Usually genetic; steroid trial limited: 2 mg/kg/day × 6 weeks, but if no response by 4 weeks, stop (to avoid toxicity).

c. Secondary NS (e.g., lupus, infection-related)

  • Dosing guided by underlying disease.

  • Lupus NS: 2 mg/kg/day (max 60 mg) × 4 weeks + taper; or IV methylpred pulses.


7. Tapering Protocols – Practical Pearls

Avoid abrupt stop:

Always taper after alternate-day phase, not during daily phase.

Example – Extended taper for high-risk relapser:

After 6+6 weeks:

  • Reduce to 1 mg/kg AD × 2 weeks

  • Then 0.5 mg/kg AD × 2 weeks

  • Then stop.

Taper traps:

Mistake Consequence
Stopping abruptly after remission Rapid relapse
Reducing to daily low-dose steroid Loss of HPA rhythm
Using every 3rd day dosing Relapse risk ↑

8. Toxicity Prevention

Complication Prevention
Cushingoid features Prefer alternate-day dosing after remission
Growth retardation AD dosing, Vitamin D & calcium
Infections Live vaccines contraindicated during high-dose
Hypertension Salt restriction, monitor BP weekly
Cataract Yearly ophthalmic review

9. Transition to Steroid-Sparing Agents (for practice)

Indication Next Step
≥2 toxic relapses or dependence Levamisole 2.5 mg/kg AD
SDNS with toxicity Cyclophosphamide 2 mg/kg/day × 12 weeks
FRNS with poor tolerance MMF 600 mg/m² BD
Calcineurin inhibitor use Tacrolimus 0.05–0.1 mg/kg/day in 2 doses

10. Practical MD-Level Scenarios & Solutions

Clinical Scenario Correct Steroid Plan Explanation
Relapse during alternate-day 0.5 mg/kg Switch to 2 mg/kg/day until remission; resume baseline dose 4 weeks AD dose insufficient; needs induction again
3rd relapse in 3 months, cushingoid Induce remission, then add levamisole; maintain on 0.3 mg/kg AD To reduce toxicity
First episode remission after 4 weeks Continue daily to complete 6 weeks; then AD 6 weeks Early remission doesn’t mean early taper
Proteinuria returns within 7 days of stopping steroids Steroid-dependent → restart 2 mg/kg/day → maintain 0.5 mg/kg AD × 6 months Defines dependence
SRNS after 8 weeks Proceed biopsy, add tacrolimus + low-dose pred 0.5 mg/kg AD Steroid resistance confirmed
Child unable to take orally due to vomiting IV methylpred 10 mg/kg/day × 3 days → switch to oral Ensures systemic delivery
Child develops varicella while on 2 mg/kg/day Stop steroids temporarily; IV acyclovir; restart after lesion crusting Prevent fatal dissemination

11. Key Pharmacologic Notes


12. Reference Sources

  1. Kliegman RM, Nelson Textbook of Pediatrics, 22nd ed., Elsevier, 2023.

  2. KDIGO Glomerular Diseases Guideline, 2021.

  3. Indian Pediatrics Nephrology Group, Consensus Statement on Management of Nephrotic Syndrome, 2021.

  4. IPNA Clinical Practice Recommendations for Idiopathic NS, 2020.

  5. Avner ED et al., Pediatric Nephrology, 8th ed. (RPS, 2022).

Bronchiolitis vs Pneumonia — How to Tell 2 of Them Apart (and What Else It Could Be)

Table of Contents(toc)

When a young child comes in with cough, difficulty breathing, and fever, one of the most important — and sometimes confusing — clinical questions is:

Is this bronchiolitis, pneumonia, or something else entirely?

1. Age and Season — The First Clues

According to Nelson, bronchiolitis is primarily a disease of infants, typically below 2 years of age, with the peak incidence between 2–6 months. It usually appears during the winter and early spring months, corresponding to RSV season.

Pneumonia, on the other hand, can occur in all age groups. Viral pneumonias are more common in infants and preschoolers, while bacterial pneumonias increase with age. There’s no strict seasonal restriction, though viral etiologies may peak in winter.


2. Etiology — The Culprit Behind It

  • Bronchiolitis:
    Caused most commonly by Respiratory Syncytial Virus (RSV) — responsible for the majority of cases in infants. Other causes include parainfluenza, influenza, human metapneumovirus, and adenovirus.

  • Pneumonia:

    • Viral — RSV, influenza, parainfluenza, adenovirus.

    • BacterialStreptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Mycoplasma pneumoniae (in older children).

In short, RSV = bronchiolitis, while bacterial pathogens = pneumonia is a good starting point, though overlap exists.


3. Pathophysiology — Where the Problem Lies

Nelson emphasizes that the site of pathology differentiates the two:

  • Bronchiolitis: Inflammation and edema of small airways (bronchioles) → obstruction → air trapping, atelectasis, and wheeze.

  • Pneumonia: Involves alveoli → consolidation, impaired gas exchange, and reduced compliance.

So, in bronchiolitis, the problem is in airflow, whereas in pneumonia, it’s in oxygen exchange.


4. Clinical Features — The Real Diagnostic Key

Feature Bronchiolitis Pneumonia
Age <2 years (especially infants) All ages
Onset Gradual, following coryzal symptoms Sudden or gradual, depending on cause
Fever Low-grade or absent Often high (especially bacterial)
Cough Prominent, paroxysmal Productive or dry
Wheeze Characteristic; diffuse Usually absent (except in viral)
Crepitations Fine, diffuse, bilateral Localized (lobar) or diffuse (interstitial)
Respiratory rate Elevated, often >60/min in infants Elevated; tachypnea proportional to severity
Feeding difficulty Common due to distress May occur if severe
Oxygen saturation May be low due to air trapping Often low due to consolidation

In bronchiolitis, wheezing and hyperinflation dominate; in pneumonia, crackles and focal findings dominate.


5. Chest X-ray — Helpful but Not Always Diagnostic

Nelson advises that radiologic findings should not be used in isolation to differentiate.
However, classic patterns help:

  • Bronchiolitis: Hyperinflated lungs, flattened diaphragm, peribronchial thickening, patchy atelectasis — no focal consolidation.

  • Pneumonia: Lobar or segmental consolidation, air bronchograms, or patchy infiltrates.


6. Response to Therapy

Another practical clue from Nelson:

  • Bronchiolitis: Poor response to antibiotics; supportive care is the mainstay (hydration, oxygen if hypoxemic).

  • Pneumonia: Marked improvement with appropriate antibiotics if bacterial.


7. Common Differentials (Nelson Mentions)

Nelson lists several conditions that mimic bronchiolitis or pneumonia:

  1. Asthma (viral-induced wheeze):

    • Often recurrent episodes.

    • Family/personal history of atopy or asthma.

    • Responds well to bronchodilators, unlike classic bronchiolitis.

  2. Pertussis:

    • Paroxysmal cough, inspiratory “whoop,” vomiting after coughing.

    • Minimal wheeze, may have leukocytosis with lymphocytosis.

  3. Foreign Body Aspiration:

    • Sudden onset, unilateral decreased air entry, localized hyperinflation or collapse.

  4. Congestive Heart Failure:

    • Tachypnea, hepatomegaly, but no true wheezing unless pulmonary edema present.

    • Cardiomegaly on chest X-ray.

  5. Aspiration Pneumonitis / GER-related:

    • History of vomiting, feeding difficulty, neurological disease.

    • Recurrent or persistent infiltrates in dependent lung areas.


8. Management Overview (as per Nelson)

  • Bronchiolitis:

    • Supportive: Oxygen, hydration, nasal suctioning.

    • Avoid routine bronchodilators, steroids, antibiotics.

    • Hospitalization: If severe distress, apnea, poor feeding, or SpO₂ < 90%.

  • Pneumonia:

    • Empiric antibiotics based on age and likely pathogen.

    • Supportive care: Oxygen, fluids, antipyretics.


9. Key Takeaway from Nelson

“Bronchiolitis should be suspected in infants with their first episode of wheezing following a viral prodrome, whereas pneumonia should be suspected in the presence of fever, focal crackles, and signs of consolidation.”

In practice, overlap exists — especially when viral pneumonia blurs the line — but understanding age, pattern, and auscultatory findings helps steer the diagnosis right.


10. Summary Table

Parameter Bronchiolitis Pneumonia
Site Bronchioles Alveoli
Age <2 years All ages
Etiology RSV (most common) Bacterial or viral
Fever Mild or absent Usually high
Wheeze Prominent Usually absent
Cough Paroxysmal Productive/dry
CXR Hyperinflation Consolidation
Treatment Supportive Antibiotics (if bacterial)

References

  • Nelson Textbook of Pediatrics, 21st Edition, Chapters 390 (Bronchiolitis) and 391 (Pneumonia).

  • Nelson Essentials of Pediatrics, 9th Edition, Section: Respiratory Disorders in Children.

Umbilical Vein Catheterization (UVC) Notes

Umbilical Vein Catheterization (UVC) Notes for Medical students and Graduates

Table of Contents(toc)
a child with umbilical vein catheter insitu cc by 4 wikimedia


Here in this note we will discuss key points in UVC most commonly asked in exams and useful practiacally.

Purpose:

  • For vascular access in neonates (especially preterm or critically ill).

  • Used for fluid, blood, medication administration, exchange transfusion, and central venous pressure (CVP) monitoring.


Indications

  • Emergency vascular access in neonates

  • Exchange transfusion

  • Administration of IV fluids, parenteral nutrition, inotropes, or antibiotics

  • Blood sampling or transfusion

  • Monitoring of central venous pressure


Contraindications

  • Omphalitis or periumbilical infection

  • Peritonitis

  • Necrotizing enterocolitis (NEC)

  • Umbilical or portal vein thrombosis

  • Imperforate or absent umbilical vein


Anatomical Background

  • Umbilical vein: single, large, thin-walled vessel at 12 o’clock position in the umbilical stump.

  • Leads to left portal vein → ductus venosus → inferior vena cava.

  • Two smaller umbilical arteries at 4 and 8 o’clock positions.


Equipment

  • Sterile gloves, drapes, antiseptic solution

  • Umbilical catheter (3.5 Fr for <1.5 kg, 5 Fr for >1.5 kg)

  • Sterile scissors, forceps, and sutures

  • 3-way stopcock and syringes

  • Normal saline for flush

  • Adhesive tape and umbilical tie

  • Sterile dressing


Procedure Steps

1. Preparation

  • Maintain aseptic technique.

  • Place baby under radiant warmer.

  • Monitor heart rate, SpO₂, and temperature.

  • Restrain limbs gently.

2. Identify Vessels

  • Clean umbilical stump with antiseptic.

  • Trim cord to ~1–2 cm from skin margin.

  • Identify one large thin-walled umbilical vein (12 o’clock) and two smaller thick-walled arteries (4 and 8 o’clock).

3. Catheter Measurement

  • Measure insertion length:

    • Formula (Shukla’s):
      [
      Length (cm) = (3 × weight [kg]) + 9 text{ cm (for term)}
      ]
      or
      [
      Length (cm) = (1.5 × birthweight [kg]) + 5.6 text{ cm (for preterm)}
      ]

    • Aim: tip at IVC–right atrial junction (high position).

4. Catheter Insertion

  • Tie umbilical tape loosely at the base of the cord.

  • Gently dilate the vein with forceps.

  • Insert catheter filled with saline (to prevent air embolism).

  • Advance slowly until free blood return is obtained.

  • For emergency use, low position (2–4 cm) acceptable until radiographic confirmation.

5. Confirmation of Position

  • Aspirate blood freely (should not be pulsatile).

  • X-ray (AP chest–abdomen) to confirm tip location:

    • High position: at T8–T9 (just above diaphragm).

    • Low position: at L3–L4 (below liver).

6. Secure Catheter

  • Tie umbilical tape firmly around cord.

  • Apply sterile dressing and tape catheter to abdomen.

  • Connect to infusion system with 3-way stopcock.

7. Documentation

  • Record catheter size, insertion length, date/time, and tip level on X-ray.


Complications

Early:

  • Malposition → hepatic or portal vein perforation

  • Air embolism

  • Arrhythmia

  • Bleeding or hematoma

  • Infection (omphalitis, sepsis)

Late:

  • Thrombosis or embolism

  • Portal hypertension

  • Hepatic necrosis

  • Catheter-related bloodstream infection


Prevention and Care

  • Strict asepsis

  • Confirm tip location before infusion of irritants

  • Daily check for signs of infection or leakage

  • Remove within 7–10 days (preferably <5 days)


Radiologic Tip Positions

Position Level (Vertebral) Comments
High T8–T9 (above diaphragm) Preferred for infusion; tip at IVC–RA junction
Low L3–L4 (below liver) Temporary/emergency; risk of hepatic injury if advanced

Key Notes

  • Never use arterial catheter for IV infusion — risk of gut necrosis.

  • Flush catheter with saline to confirm patency before use.

  • If resistance is met → stop and recheck direction; never force insertion.

  • In case of doubt, remove and reattempt under sterile precautions.

Below is the video for umbilical vein catheterization guide.

Exit mobile version